Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $8

Benzinga · 6d ago
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $7 to $8.